BioCentury | Feb 28, 2020
Deals

Biogen expands its modality toolkit in Alzheimer’s and Parkinson’s with Sangamo deal

In its latest CNS partnership, Biogen is doubling down on targets already in its pipeline with a gene regulation technology from Sangamo it hopes will shut down target expression altogether. By closing off target expression,...
BC Extra | Dec 13, 2019
Clinical News

Phase II miss dims outlook for Biogen’s anti-tau mAb from Bristol deal

Biogen is terminating development of gosuranemab to treat primary tauopathies following a mid-stage clinical failure, but the move won’t scuttle a Phase II trial of the anti-tau mAb to treat Alzheimer’s disease. Biogen Inc. (NASDAQ:BIIB)...
BioCentury | Nov 8, 2019
Emerging Company Profile

Arkuda emerges from Atlas with genetic dementia program

Atlas-founded Arkuda is developing compounds for frontotemporal dementia due to genetic lysosomal deficits that could be applied to other neurodegenerative diseases linked to lysosomal dysfunction. Arkuda Therapeutics Inc. debuted Thursday with a $44 million series...
BioCentury | Jun 22, 2019
Product Development

Is tau the new amyloid?

After finally getting the message that they need to look beyond amyloid to treat Alzheimer’s disease, pharmas are lining up behind tau as the next big target. The question is whether they can pick out...
BC Week In Review | Feb 1, 2019
Clinical News

Roche stops crenezumab trials in early Alzheimer's for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback on Jan. 30 after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc....
BC Extra | Jan 30, 2019
Clinical News

Roche stops crenezumab trials in early Alzheimer’s for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback Wednesday after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc. unit has...
BC Week In Review | Dec 1, 2017
Clinical News

Genentech begins Phase II of AC Immune's anti-Tau mAb for AD

AC Immune S.A. (NASDAQ:ACIU) said the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) started a Phase II trial of Anti Tau mAb (RO7105705) to treat prodromal-to-mild Alzheimer's disease. The trial start triggered a CHF14 million...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
BC Extra | Nov 23, 2016
Clinical News

Lilly's solanezumab fails third Phase III Alzheimer's test

Eli Lilly and Co. (NYSE:LLY) lost nearly $9 billion in market cap on Wednesday when it said it was abandoning efforts to submit solanezumab ( LY2062430 ) for regulatory approval to treat mild dementia in Alzheimer’s disease...
BioCentury | Oct 24, 2016
Finance

Luck favors the prepared

A year’s worth of preparation for a U.S. IPO put Swiss biotech AC Immune S.A. (NASDAQ:ACIU) in the perfect position to thread the needle between the Brexit fallout and volatility around the U.S. elections. That...
Items per page:
1 - 10 of 16